Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series

• Main Authors: Michael S. Yule (Author), Joshua Thompson (Author), Khachonphat Leesahatsawat (Author), Mariana S. Sousa (Author), Stefan D. Anker (Author), Jann Arends (Author), Trude R. Balstad (Author), Leo R. Brown (Author), Asta Bye (Author), Olav Dajani (Author), Marie Fallon (Author), Marianne J. Hjermstad (Author), Gunnhild Jakobsen (Author), James McDonald (Author), Josh McGovern (Author), Eric J. Roeland (Author), Judith Sayers (Author), Richard J.E. Skipworth (Author), Inger O. Ottestad (Author), Iain Philips (Author), Melanie R. Simpson (Author), Tora S. Solheim (Author), Ola Magne Vagnildhaug (Author), Donald McMillan (Author), Barry J.A. Laird (Author), Ross D. Dolan (Author), the Cancer Cachexia Endpoints Working Group (Author)
• Format: Book
• Published: Wiley, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Regulatory agencies require evidence that endpoints correlate with clinical benefit before they can be used to approve drugs. Biomarkers are often considered surrogate endpoints. In cancer cachexia trials, the measurement of biomarkers features frequently. The aim of this systematic review...